Questions
1. Does the diagnosis of true CLL vs monoclonal B-cell lymphocytosis with CLL phenotype affect prognostic evaluation? 2. Is there evidence that prognostic laboratory evaluation should be done in patients with CLL at the earliest clinical stages?
Upon completion of this activity you will be able to:
• describe the differences between chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis and how they impact laboratory testing for prognosis.
• discuss the most commonly evaluated laboratory tests used for
prognosis in CLL.
• analyze the results of the prognostic evaluation to determine whether a patient is high or low risk for disease progression.
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Questions appear on p 826. Exam is located at www.ascp.org/ajcpcme. Defining CLL and Monoclonal B-Cell Lymphocytosis Is Important for Prognosis CLL is the most common adult leukemia affecting the Western world, with an incidence of about 4 per 100,000 and a median age at diagnosis between 70 and 80 years (>80% diagnosed after age 60 years). 1 World Health Organization (WHO) criteria define CLL as greater than or equal to 5.0 × 10 9 /L monoclonal B cells in peripheral blood. The monoclonal mature B lymphocytes show dense, aggregated chromatin, and the typical immunophenotype demonstrates CD19+ CD20dim+ CD5+ CD23+ CD10-B cells with dim surface light-chain restriction. 2 As the elderly population expands and flow cytometric immunophenotyping increasingly provides a very high level of detection, more individuals are incidentally found to have a small population (<5.0 × 10 9 /L) of circulating monoclonal B cells with these CLL-specific markers, an entity defined as monoclonal B-cell lymphocytosis (MBL) with a CLL phenotype. 3, 4 MBL represents a premalignant B-cell state similar to monoclonal gammopathy of uncertain significance. About 3% to 4% of the "healthy" population can be shown to have MBL. 5 One analysis has shown that MBL always precedes CLL, with a range of 6 months to 6 years, 6 but it is estimated that only 1% to 2% of patients with MBL will progress to CLL each year. 7, 8 Interestingly, MBL carries the identical frequency of cytogenetic abnormalities (11p-, 13q-, 17p-, and trisomy 12) 9 and immunoglobulin heavy chain variable (IGHV) gene mutations, 6 yet its clinical status as an indolent "premalignant" condition trumps all other prognostic data. 10 It has yet to be elucidated whether a pathogenetic subgroup of MBL will subsequently predict which patients will later develop CLL. Thus, the recommended management of patients with MBL is an annual physical examination and complete blood count; no other laboratory studies or invasive procedures are warranted due to the very low progression rate of MBL to CLL. 10 
Clinical Staging of CLL Is Most Useful for Patients Beyond the Earliest Stage
Risk stratification is critical for disease management since the median survival for all patients with CLL is widely variable and, depending on prognostic factors, ranges from 18 months to greater than 10 years. Treatment has traditionally been reserved for patients with active disease that includes anemia or thrombocytopenia, lymphadenopathy, hepatosplenomegaly, progressive lymphocytosis (doubling time of <12 months), or severe constitutional symptoms. 11 In addition, age and performance status (often related) based on clinical evaluation will likely affect whether a patient is eligible for aggressive therapy. Two clinical staging criteria-the Rai system (common in North America) and the Binet system (widely used throughout Europe) 12,13 -classify patients into 3 relatively parallel groups with distinct prognoses ❚Table 1❚.
Patients in the lowest clinical stage are currently treated expectantly (watch and wait) because of the extreme heterogeneity in the time until therapy is required, especially with elderly patients, who may never require specific CLL treatment and will die of unrelated causes. Although preventing many patients from unnecessary therapy, this strategy ensures that some patients with CLL will evolve to an aggressive course, which does not subsequently respond to eventual treatment. The impetus for better defining high-risk CLL rests on the concept that modern chemoimmunotherapy at a stage of low tumor burden will decrease the incidence of clonal evolution and prolong survival. A retrospective study of patients with Binet stage A CLL suggests that patients with 2 or more risk factors (high thymidine kinase or b 2 -microglobulin, lymphocytosis >13 × 10 9 /L, and CD38 positivity) will Lymphocytosis and Hb <11.0 g/dL (± lymphadenopathy/hepatosplenomegaly) IV Lymphocytosis and platelets <100 × 10 9 /L (± lymphadenopathy/hepatosplenomegaly) Binet system A Hb ≥10.0 g/dL, platelets ≥100 × 10 9 /L, <3 lymph node regions involved 9 B Hb ≥10.0 g/dL, platelets ≥100 × 10 9 /L, ≥3 lymph node regions involved 5 C Hb <10.0 g/dL or platelets <100 × 10 9 /L 2 Hb, hemoglobin.
progress faster to a need for therapy than those with a 0 to 1 risk factor. 14 IGHV mutational status was a similarly powerful discriminator of progression, and (although not specifically examined) the study did not preclude detection of 17p-at diagnosis as another prognostic marker. 14 Therefore, it may be important to compare expectant therapy with a more aggressive, but selective, strategy for early treatment of individuals with CLL with laboratory evidence of poorer outcome. Indeed, as more treatment options become viable for patients with CLL, especially those with low to intermediate risk, more laboratory assays may be clinically validated to gauge individual patient prognosis and guide treatment strategy. ❚Table 2❚ lists current laboratory analyses that are used to assess CLL prognosis. Some of the listed assays [15] [16] [17] [18] [19] [20] are still investigational, albeit promising, and will not be further discussed in this review.
Validity of Prognostic Laboratory Assays in CLL
Somatic hypermutation in the rearranged IGHV genes in CLL cells confers a better prognosis than those that lack hypermutation. 21, 22 IGHV genes encode the antigen-binding domain of the B-cell antigen receptor (surface immunoglobulin). In 1 study, patients with mutated IGHV genes (<98% identity to germline) had a median survival of more than 25 years, whereas those who had unmutated genes (≥98% identity) had a median survival of less than 8 years. 21, 22 IGHV mutational status at diagnosis tends to remain constant over the course of disease, and its prognostic value has been confirmed in numerous subsequent studies.
There is some correlation between IGHV mutational status and CLL expression of CD38. This transmembrane glycoprotein reflects proliferative status and modulates intracellular signaling. Nearly all patients with CLL with 30% or more monoclonal B cells expressing CD38 have unmutated IGHV genes and higher levels of monoclonal lymphocytosis, 23, 24 and this patient group also has shorter overall survival [22] [23] [24] and a briefer interval to treatment. 25 However, CD38 expression and IGHV gene status have been shown to be discordant in up to 30% of patients at CLL diagnosis, 23 and in clinical trials, IGHV analysis has been held as the more reliable indicator for prognosis. 26 Technical challenges rarely arise in assessing IGHV status; therefore, although CD38 analysis is often performed at diagnosis, IGHV status is the more definitive prognostic marker. Since CD38 has been shown to be dynamic throughout the CLL disease course, possibly representing proliferative activity, 27 an upward trend in expression may be useful as a real-time indicator of disease progression. 28 The z-associated protein, with a molecular weight of 70 kDa (ZAP-70), is another potential surrogate for IGHV gene status. Intracellular ZAP-70 expression (≥30% of CLL cells) nearly always demonstrates an unmutated IGHV gene 29, 30 and, like CD38, ZAP-70 expression can be quantitated by routine flow cytometric evaluation. However, ZAP-70 has even poorer concordance with IGHV status than CD38. 31, 32 Moreover, the quality control for quantitation of ZAP-70 is subjectively based on either natural killer/T-cell or normal B-cell populations, which may not be present in particular patients with CLL. ZAP-70 expression has also been noted to have both significant variability between laboratory tests and deterioration of expression over time. 33 The latter caveat is especially problematic if the patient sample is sent to a reference laboratory. Hence, it is unlikely that ZAP-70 can replace determination of IGHV gene status.
Although atypical lymphocyte morphology and elevated doubling time (<12 months) are cited for predicting outcome, the former is too subjective to be a reliable indicator, and the latter evaluation generally cannot be accomplished at diagnosis. Serum levels of b 2 -microglobulin and thymidine kinase have been demonstrated to be independent biological predictors of progression-free survival, especially in early stage CLL. 14 The former test is readily available and should be part of the prognostic evaluation for CLL if multiple prognostic assays are being evaluated for treatment decisions; however, thymidine kinase is not widely available as a clinically 34 and genes that may be critical for refractoriness to therapy (SF3B1, NOTCH1, and BIRC3). 26 Most reference laboratories provide fluorescence in situ hybridization (FISH) panels, which specifically incorporate conserved cytogenetic abnormalities as prognostic variables in CLL, including trisomy 12, and deletions of 11q, 13q, and 17p. 35 Deletion of 13q is the most common finding in CLL and does not convey clear risk changes, but trisomy 12 generally confers a better prognosis. By contrast, 11q-and 17p-are poor prognostic indicators. 26 In particular, deletion of 17p13 always includes the TP53 tumor suppressor gene, and more than 80% of monoallelic 17p-patients with CLL will have a mutation in the remaining TP53 gene. Moreover, multiple studies show that patients with 17p-or definitive TP53 deletion/mutation will have extremely brief progression-free intervals after chemotherapy for CLL and rarely go into remission. 26, [35] [36] [37] Thus, detection of 17p-or TP53 deletion/ mutation should move patients into the highest risk category within any clinical stage of CLL.
Proposed Laboratory Risk Stratification for Incidental/Early Stage CLL
Because of their low risk for progressing to CLL, patients with MBL do not require prognostic marker evaluation and should be expectantly followed. Second-line patients with CLL with an advanced clinical stage (Rai III-IV or Binet B-C) generally require therapy no matter what their prognostic assays show. It is truly the low clinical stage (Rai 0-II, Binet A) patients with CLL who most need evaluation of prognostic markers to place them into high-and low-risk categories ❚Figure 1❚. 38 The subgroup at lowest risk for progression has a mutated IGHV status, no 11q deletion or 17q deletion/TP53 mutation, lymphocyte doubling time greater than 12 months, and a normal b 2 -microglobulin. Low clinical stage patients with CLL who are at high risk for progression will have 1 of the following: unmutated IGHV status, 17q deletion or TP53 deletion/mutation, or the combination of at least 2 other risk factors, including 11q-, high CD38, significant (>13 × 10 9 /L) monoclonal lymphocytosis, and elevated b 2 -microglobulin. Such patients should be considered for clinical trials of early intervention vs watchful waiting.
Case Summary
Our patient meets the phenotypic and WHO criteria for CLL; he has more than 5 × 10 9 /L monoclonal B lymphocytes and thus does not have MBL. The patient's low clinical stage (absence of organomegaly and lymphadenopathy), low b 2 -microglobulin, and lack of CD38 expression place him in a group that would generally be characterized by long-term progression-free survival. However, he presents at a much younger age than the median for CLL; therefore, laboratory studies to determine prognosis are recommended, including blood for IGHV gene status and marrow for karyotype and FISH panel. These tests respectively reveal an unmutated (100% germline) IGHV gene and 13q-. After discussion between the patient and his hematologist, the patient is referred to a National Institutes of Health cancer center with active clinical trials for CLL. 
